Medpace (NASDAQ:MEDP) Issues Quarterly Earnings Results, Beats Expectations By $0.27 EPS

Medpace (NASDAQ:MEDP) released its quarterly earnings data on Wednesday. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27, FiscalAI reports. Medpace had a return on equity of 109.14% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the previous year, the business posted $3.10 EPS. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace updated its FY 2026 guidance to 17.250-17.950 EPS.

Medpace Price Performance

Medpace stock traded down $3.46 during mid-day trading on Friday, hitting $602.36. 95,668 shares of the company’s stock traded hands, compared to its average volume of 356,351. The firm has a 50 day simple moving average of $488.37 and a two-hundred day simple moving average of $493.74. The stock has a market cap of $17.20 billion, a price-to-earnings ratio of 35.39, a P/E/G ratio of 2.64 and a beta of 1.15. Medpace has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Robert W. Baird raised their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday. TD Cowen reaffirmed a “hold” rating on shares of Medpace in a research note on Friday. Mizuho set a $665.00 target price on Medpace in a report on Friday. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Finally, Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $531.67.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace delivered better-than-expected Q2 results, with earnings per share of $4.25 and revenue of $707.33 million, both ahead of estimates; revenue also climbed 17.2% year over year. Article Title
• Positive Sentiment: The company raised its FY2026 guidance, signaling confidence in continued growth and stronger operating performance ahead. Article Title
• Positive Sentiment: Bookings improved materially, with a stronger book-to-bill ratio and backlog conversion, which supports future revenue visibility and helped fuel investor optimism. Article Title
• Neutral Sentiment: Robert W. Baird raised its price target on Medpace to $624 from $547 but kept a neutral rating, implying the stock may have already priced in much of the near-term upside. Article Title

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Medpace

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its position in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares during the period. Wasatch Advisors LP lifted its holdings in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the period. Invesco Ltd. grew its position in shares of Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after buying an additional 85,517 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its stake in shares of Medpace by 1,527.8% in the third quarter. Qube Research & Technologies Ltd now owns 74,780 shares of the company’s stock valued at $38,449,000 after buying an additional 70,186 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.